{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":51,"searchCount":0},"additional":{"submitter":["Harausz EP"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS"],"pagination":["92-6"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4864490"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["98"],"pubmed_abstract":["Nitazoxanide (NTZ) and its metabolite tizoxanide (TIZ) were studied as antimycobacterial agents in vitro (in mycobacterial growth indicator tube [MGIT] cultures) and in a whole blood bactericidal assay. Both NTZ and TIZ show high protein binding. In MGIT cultures (albumin concentration = 78 μM), inhibition of Mycobacterium tuberculosis growth occurred at total drug concentrations of ≥16 μg/ml, whereas in whole blood cultures (albumin concentration = 350 μM), ≥128 μg/ml was required. Free drug fractions at these two conditions were estimated to be 69% and 2%, respectively. Co-incubation of NTZ and TIZ in human plasma for 72 h nearly completely eliminated their ability to inhibit mycobacterial growth in MGIT. Interactions with plasma proteins may limit the potential of NTZ and TIZ as drugs for human tuberculosis."],"journal":["Tuberculosis (Edinburgh, Scotland)"],"pubmed_title":["Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture."],"pmcid":["PMC4864490"],"funding_grant_id":["N01AI70022","HHSN266200700022C/NO1-AI-70022","N01 AI070022","T32 AI007024"],"pubmed_authors":["Wallis RS","Boom WH","Jacobs MR","Sanchez-Felix M","Chervenak KA","Good CE","Harausz EP","TB Research Unit (TBRU) at Case Western Reserve University"],"view_count":["51"],"additional_accession":[]},"is_claimable":false,"name":"Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.","description":"Nitazoxanide (NTZ) and its metabolite tizoxanide (TIZ) were studied as antimycobacterial agents in vitro (in mycobacterial growth indicator tube [MGIT] cultures) and in a whole blood bactericidal assay. Both NTZ and TIZ show high protein binding. In MGIT cultures (albumin concentration = 78 μM), inhibition of Mycobacterium tuberculosis growth occurred at total drug concentrations of ≥16 μg/ml, whereas in whole blood cultures (albumin concentration = 350 μM), ≥128 μg/ml was required. Free drug fractions at these two conditions were estimated to be 69% and 2%, respectively. Co-incubation of NTZ and TIZ in human plasma for 72 h nearly completely eliminated their ability to inhibit mycobacterial growth in MGIT. Interactions with plasma proteins may limit the potential of NTZ and TIZ as drugs for human tuberculosis.","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 May","modification":"2024-11-13T10:59:24.042Z","creation":"2019-03-27T02:13:31Z"},"accession":"S-EPMC4864490","cross_references":{"pubmed":["27156623"],"doi":["10.1016/j.tube.2016.03.002"]}}